

Appendix: Tables

1.	Sales January to September 2026 and 2025	2
2.	Quarterly sales and constant exchange rate sales growth by Division in 2026 and 2025	3
3.	Product sales Pharmaceuticals Division and constant exchange rate growth YTD September 2026 vs. YTD September 2025	4
4.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth	6
5.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States	7
6.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe	8
7.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan	9
8.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International	10

1. Sales January to September 2026 and 2025

CHF millions	Nine months ended 30 September		% change	
	2026	2025	At CER	In CHF
Pharmaceuticals Division	36,212	35,555	7	2
United States	18,712	18,798	5	0
Europe	6,819	6,818	2	0
Japan	2,352	2,139	25	10
International	8,329	7,800	10	7
Diagnostics Division	10,281	10,307	4	0
Roche Group	46,493	45,862	6	1

International: Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

2. Quarterly sales and constant exchange rate sales growth by Division in 2026 and 2025

CHF millions	Q3 2025	% change vs. Q3 2024	Q4 2025	% change vs. Q4 2024	Q1 2026	% change vs. Q1 2025	Q2 2026	% change vs. Q2 2025	Q3 2026	% change vs. Q3 2025
Pharmaceuticals Division	11,570	7	12,114	9	11,469	7	12,160	6	12,583	8
United States	6,128	5	6,557	9	5,693	5	6,536	7	6,483	5
Europe	2,252	5	2,346	7	2,234	-1	2,286	3	2,299	2
Japan	714	6	743	4	649	14	711	9	992	49
International	2,476	11	2,468	16	2,893	16	2,627	4	2,809	11
Diagnostics Division	3,348	2	3,540	6	3,253	3	3,482	4	3,546	5
Roche Group	14,918	6	15,654	8	14,722	6	15,642	5	16,129	7

International: Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

3. Product sales Pharmaceuticals Division and constant exchange rate growth YTD September 2026 vs. YTD September 2025

CHF millions	Total		United States		Europe		Japan		International	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Ocrevus	5,317	7	3,581	5	1,136	9	-	-	600	21
Hemlibra	3,750	12	2,006	9	769	5	291	20	684	23
Vabysmo	3,196	10	2,060	2	585	7	131	41	420	65
Tecentriq	2,615	5	1,243	8	626	-2	245	6	501	9
Xolair	2,521	20	2,521	20	-	-	-	-	-	-
Phesgo	2,064	18	486	-1	657	11	152	24	769	43
Perjeta	2,040	-8	824	-10	361	-13	38	-20	817	-3
Actemra/RoActemra	1,621	-10	795	-9	328	-26	232	14	266	-4
Evrysdi	1,470	18	497	12	504	14	65	7	404	33
Kadcyla	1,339	-9	442	-19	370	-5	65	9	462	-2
Polivy	1,302	24	606	29	204	-9	176	30	316	44
Alecensa	1,213	6	391	-1	189	-3	154	15	479	15
MabThera/Rituxan	919	3	605	12	94	-8	8	-16	212	-10
Activase/TNKase	830	6	792	5	-	-	-	-	38	12
Gazyva	751	7	369	4	176	-2	28	28	178	25
Herceptin	695	-12	140	-15	205	-6	3	-35	347	-13
Avastin	639	-12	195	-8	56	5	56	-43	332	-9
Columvi	327	67	146	24	92	113	-	-	89	167
Enspryng	319	28	79	18	34	18	138	30	68	42
Pulmozyme	303	-12	214	-11	43	-11	1	38	45	-18
Elevidys	291	37	-	-	2	-	40	-	249	16
Lunsumio	206	187	108	155	14	-15	78	*	6	79
Xofluza	185	-24	37	24	3	46	-	-	145	-32

Itovebi	163	153	129	124	12	*	-	-	22	308
Rozlytrek	102	-8	25	-28	18	8	4	-9	55	1
PiaSky	52	74	1	207	11	138	39	61	1	58
Cotellic	35	5	17	9	7	-5	-	-	11	6
Luxturna	26	-29	26	-29	-	-	-	-	-	-
Susvimo	12	107	12	106	-	-	-	-	-	-
Pharma other	1,909	-1	365	-13	323	-3	408	47	813	-11
Pharma total sales	36,212	7	18,712	5	6,819	2	2,352	25	8,329	10

International: Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

* Over 500%

4. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth

CHF millions	Q3 2025	% change vs. Q3 2024	Q4 2025	% change vs. Q4 2024	Q1 2026	% change vs. Q1 2025	Q2 2026	% change vs. Q2 2025	Q3 2026	% change vs. Q3 2025
Ocrevus	1,684	6	1,820	16	1,692	6	1,778	7	1,847	9
Hemlibra	1,105	4	1,228	8	1,190	13	1,302	9	1,258	13
Vabysmo	996	4	1,039	7	1,024	13	1,035	3	1,137	13
Tecentriq	883	4	950	8	811	4	893	9	911	3
Xolair	781	34	849	26	708	26	965	28	848	8
Phesgo	630	51	614	34	686	27	632	9	746	18
Perjeta	703	-14	652	-13	672	-11	717	-3	651	-9
Actemra/RoActemra	614	-2	577	-10	534	-4	540	-14	547	-11
Evrysdi	424	10	464	26	464	19	504	16	502	18
Kadcyla	494	7	494	6	439	-4	477	-7	423	-15
Polivy	371	30	369	31	407	26	401	14	494	33
Alecensa	388	8	372	1	401	12	394	1	418	6
MabThera/Rituxan	303	3	318	-3	292	10	317	0	310	1
Activase/TNKase	283	1	274	-2	255	-2	300	24	275	-4
Gazyva	238	13	258	15	247	10	242	4	262	9
Herceptin	257	-15	211	-29	234	-12	228	-12	233	-11
Avastin	241	-11	210	-21	224	-9	190	-20	225	-8
Columvi	79	71	86	64	95	77	101	64	131	63
Enspryng	92	25	95	17	96	31	99	15	124	37
Pulmozyme	122	26	118	1	89	-18	115	3	99	-20

5. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States

CHF millions	Q3 2025	% change vs. Q3 2024	Q4 2025	% change vs. Q4 2024	Q1 2026	% change vs. Q1 2025	Q2 2026	% change vs. Q2 2025	Q3 2026	% change vs. Q3 2025
Ocrevus	1,151	1	1,261	17	1,117	3	1,183	2	1,281	10
Hemlibra	617	-1	724	6	613	15	700	4	693	11
Vabysmo	689	-4	718	-1	652	4	681	-2	727	4
Tecentriq	403	2	418	4	378	6	437	12	428	5
Xolair	781	34	849	26	708	26	965	28	848	8
Phesgo	175	29	185	22	159	2	159	-2	168	-5
Perjeta	291	-6	300	4	263	-12	288	-10	273	-8
Actemra/RoActemra	307	-6	280	-19	248	-3	267	-13	280	-10
Evrysdi	159	18	144	0	160	15	163	15	174	8
Kadcyla	181	2	191	10	156	-11	154	-17	132	-28
Polivy	170	18	191	32	171	26	210	29	225	32
Alecensa	144	15	145	4	105	-7	156	13	130	-10
MabThera/Rituxan	188	5	219	5	183	16	219	13	203	7
Activase/TNKase	270	1	259	-2	244	-2	287	24	261	-5
Gazyva	123	14	143	20	115	1	125	8	129	3
Herceptin	54	-6	50	-14	44	-16	50	-13	46	-18
Avastin	69	-16	74	-14	59	-15	66	-8	70	0
Columvi	47	90	53	70	43	35	48	23	55	17
Enspryng	25	9	26	1	22	20	28	20	29	15
Pulmozyme	87	30	89	8	58	-21	87	11	69	-22

6. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe

CHF millions	Q3 2025	% change vs. Q3 2024	Q4 2025	% change vs. Q4 2024	Q1 2026	% change vs. Q1 2025	Q2 2026	% change vs. Q2 2025	Q3 2026	% change vs. Q3 2025
Ocrevus	354	12	391	14	363	9	395	11	378	7
Hemlibra	247	14	262	12	252	5	250	3	267	8
Vabysmo	178	9	185	13	190	0	196	10	199	11
Tecentriq	216	0	228	7	202	-6	208	-1	216	0
Xolair	-	-	-	-	-	-	-	-	-	-
Phesgo	201	9	210	9	206	7	219	10	232	15
Perjeta	136	-14	134	-7	119	-15	119	-12	123	-10
Actemra/RoActemra	142	-1	138	-7	124	-16	114	-27	90	-36
Evrysdi	158	7	166	21	159	13	176	21	169	8
Kadcyla	130	-5	136	0	123	-6	125	-3	122	-7
Polivy	68	21	62	26	63	-32	65	1	76	12
Alecensa	64	-10	65	-3	63	-5	63	-2	63	-1
MabThera/Rituxan	34	13	36	-13	31	-8	31	-9	32	-7
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Gazyva	62	1	62	5	57	-2	60	-1	59	-5
Herceptin	73	2	68	-9	69	-7	67	-6	69	-5
Avastin	28	47	16	-22	14	3	21	76	21	-25
Columvi	18	51	19	65	21	84	32	142	39	110
Enspryng	11	37	10	36	11	20	12	21	11	13
Pulmozyme	15	-3	16	-9	15	-14	14	-7	14	-11

7. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan

CHF millions	Q3 2025	% change vs. Q3 2024	Q4 2025	% change vs. Q4 2024	Q1 2026	% change vs. Q1 2025	Q2 2026	% change vs. Q2 2025	Q3 2026	% change vs. Q3 2025
Ocrevus	-	-	-	-	-	-	-	-	-	-
Hemlibra	92	11	102	5	81	18	90	3	120	40
Vabysmo	35	17	41	15	37	39	38	16	56	68
Tecentriq	88	-1	87	-6	69	0	77	-4	99	21
Xolair	-	-	-	-	-	-	-	-	-	-
Phesgo	49	41	49	11	42	23	46	8	64	39
Perjeta	17	-27	15	-31	12	-19	12	-26	14	-15
Actemra/RoActemra	78	4	80	6	66	9	74	7	92	26
Evrysdi	22	7	22	-9	18	4	21	-5	26	24
Kadcyla	23	-2	23	-7	19	6	20	-1	26	23
Polivy	54	14	54	5	46	24	52	10	78	54
Alecensa	51	13	53	7	43	4	50	12	61	27
MabThera/Rituxan	4	-3	3	-11	3	-6	3	-16	2	-26
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Gazyva	8	22	10	37	9	28	8	0	11	60
Herceptin	2	-30	1	-33	1	-24	1	-47	1	-33
Avastin	35	-19	34	-21	21	-29	15	-56	20	-41
Columvi	-	-	-	-	-	-	-	-	-	-
Enspryng	42	22	44	20	35	13	44	22	59	52
Pulmozyme	-	13	1	-21	-	43	-	14	1	59

8. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International

CHF millions	Q3 2025	% change vs. Q3 2024	Q4 2025	% change vs. Q4 2024	Q1 2026	% change vs. Q1 2025	Q2 2026	% change vs. Q2 2025	Q3 2026	% change vs. Q3 2025
Ocrevus	179	35	168	11	212	24	200	37	188	6
Hemlibra	149	9	140	18	244	14	262	39	178	18
Vabysmo	94	111	95	118	145	126	120	24	155	64
Tecentriq	176	17	217	25	162	14	171	20	168	-5
Xolair	-	-	-	-	-	-	-	-	-	-
Phesgo	205	213	170	122	279	78	208	19	282	36
Perjeta	259	-21	203	-30	278	-9	298	10	241	-10
Actemra/RoActemra	87	7	79	6	96	5	85	-10	85	-6
Evrysdi	85	4	132	116	127	40	144	14	133	54
Kadcyla	160	28	144	9	141	5	178	1	143	-11
Polivy	79	105	62	67	127	120	74	-7	115	38
Alecensa	129	8	109	-3	190	39	125	-13	164	21
MabThera/Rituxan	77	-5	60	-22	75	6	64	-24	73	-10
Activase/TNKase	13	18	15	-4	11	-4	13	29	14	13
Gazyva	45	24	43	8	66	45	49	-1	63	32
Herceptin	128	-25	92	-42	120	-14	110	-14	117	-12
Avastin	109	-13	86	-26	130	-1	88	-26	114	1
Columvi	14	48	14	45	31	204	21	135	37	158
Enspryng	14	60	15	32	28	93	15	-11	25	52
Pulmozyme	20	34	12	-19	16	-12	14	-24	15	-17

International: Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others